Managing Crohn disease in children and adolescents: Focus on tumor necrosis factor antagonists

被引：4
作者：
Saeed S.A. [1 ]
Crandall W.V. [2 ,3 ]
机构：
[1] Division of Pediatric Gastroenterology and Nutrition Sciences, University of Alabama at Birmingham, Birmingham, AL
[2] Division of Gastroenterology, Hepatology and Nutrition, Nationwide Children's Hospital, Ohio State University, Columbus, OH
[3] Columbus, OH 43205
来源：
Pediatric Drugs | 2008年 / 10卷 / 1期
关键词：
Adalimumab; therapeutic use; Adolescents; CDP; 571; Certolizumab pegol; Children; Crohn's disease; treatment; Etanercept; Infliximab; Research and development; Semapimod;
D O I：
10.2165/00148581-200810010-00004
中图分类号：
学科分类号：
摘要：
Crohn disease (CD) is a chronic inflammatory disorder of the gastrointestinal tract characterized by a relapsing course and variable presentation that often includes abdominal pain, diarrhea, and fatigue. CD frequently presents during childhood, resulting in pediatric-specific complications, such as growth failure and delayed puberty. Conventional drug therapy for moderate to severe pediatric CD includes induction of remission with corticosteroids, and maintenance of remission with immunomodulators. Patients who have an inadequate response to standard therapy are being increasingly treated with anti-tumor necrosis factor-α (TNFα) agents. Infliximab has been the most widely studied anti-TNFα agent in pediatric CD, and has been shown to be efficacious in this condition. Adalimumab has been proven to be efficacious in adults with CD, but there has been only a single case report in children. CDP571 has been tested in 20 children with CD, showing some efficacy. Finally, thalidomide therapy has been associated with improvement in two small case series. Toxicities of these agents include infusion reactions, infections, malignancies, neurologic disorders, and hematologic derangements. © 2008 Adis Data Information BV. All rights reserved.
引用
收藏
页码：31 / 38
页数：7
相关论文
共 68 条
  • [1] Barton J.R., Gillon S., Ferguson A., Incidence of inflammatory bowel disease in Scottish children between 1968 and 1983
  • [2] marginal fall in ulcerative colitis, three fold rise in Crohn's disease, Gut, 30, pp. 618-622, (1989)
  • [3] Langholz E., Munkholm P., Kraslinikoff P.A., Et al., Inflammatory bowel diseases with onset in childhood. Clinical features, morbidity and mortality in a regional cohort, Scand J Gastroenterol, 32, pp. 139-147, (1997)
  • [4] Kugathasan S., Judd R.H., Hoffman R.G., Et al., Epidemiologic and clinical characteristics of children with newly diagnosed inflammatory bowel disease in Wisconsin: A state-wide population based study, J Pediatr, 143, pp. 525-531, (2003)
  • [5] Bjornsson S., Johansson J.H., Inflammatory bowel disease in Iceland, 1990-1994: A prospective, nationwide, epidemiological study, Eur J Gatroenterol Hepatol, 12, pp. 31-38, (2000)
  • [6] Baldassano R.N., Piccoli D.A., Inflammatory bowel disease in pediatric and adolescent patients, Gastroenterol Clin North Am, 28, pp. 445-458, (1999)
  • [7] Mamula P., Markowitz J.E., Baldassano R.N., Inflammatory bowel disease in early childhood and adolescents: Special considerations, Gastroenterol Clin North Am, 32, pp. 967-995, (2003)
  • [8] Sands B.E., Why do anti-tumor necrosis factor antibodies work in Crohn's disease?, Rev Gastroenterol Disord, 4, SUPPL. 3, (2004)
  • [9] Papadakis K.A., Targan S.R., Tumor necrosis factor: Biology and therapeutic inhibitors, Gastroenterology, 119, pp. 1148-1157, (2000)
  • [10] Dieu M.C., Vanbervliet B., Vicari A., Et al., Selective recruitment of immature and mature dendritic cells by distinct chemokines expressed in different anatomic sites, J Exp Med, 188, pp. 373-386, (1998)
1234567